Shanghai Henlius Biotech
Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Henlius Biotech's score of 29 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shanghai Henlius Biotech's reported carbon emissions
In 2023, Shanghai Henlius Biotech reported total carbon emissions of approximately 21,973,000 kg CO2e, comprising 6,908,630 kg CO2e from Scope 1, 15,064,370 kg CO2e from Scope 2, and 21,973,000 kg CO2e from Scope 3 emissions. This marks a slight increase in emissions compared to previous years, with total emissions recorded at about 19,667,960 kg CO2e in 2020 and 23,543,440 kg CO2e in 2021. The company has disclosed emissions data for Scope 1, 2, and 3, indicating a comprehensive approach to tracking its carbon footprint. However, there are currently no specific reduction targets or initiatives outlined in their climate commitments. This lack of defined reduction strategies suggests that while Henlius is monitoring its emissions, it may need to establish clearer goals to align with industry standards for climate action. Overall, Shanghai Henlius Biotech's emissions data reflects the challenges faced by the biopharmaceutical sector in managing carbon outputs, highlighting the need for ongoing commitment to sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 3,427,130 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,168,490 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Henlius Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
